The asymptomatic follicular lymphoma (AFL) trial: single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma

Chonlada Laoruangroj, Pamela J. Atherton, Gregory A. Wiseman, Stephen Ansell, Andrew L. Feldman, Peyton Schumacher, Thomas E. Witzig

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'The asymptomatic follicular lymphoma (AFL) trial: single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences